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(LSD) resulting from the deficiency of the lysosomal enzyme ␣-gal (EC 3.2.1. 22 ). This enzymatic defect leads However, the unavailability of sufficient amounts of the purified human enzyme has prevented a proper evaluto the deposition of neutral glycosphingolipids in most tissues, the pathological and clinical manifestations of the ation of the efficacy of replacement therapy so far. Alternative ways of providing a source of active disease being the result of progressive accumulation in endothelial cells leading to ischemia and infarction in enzyme for the treatment of LSD have included bone marrow transplantation and, more recently, gene transfer organs like kidney, heart or brain. 1 In addition to the sorting mechanisms operating in the into haematopoietic stem cells or enzyme delivery into the whole organism by genetically modified cells. 4 For trans-Golgi network, lysosomal enzymes can also be recaptured from the extracellular space via mannose-6-instance, it has been recently shown that fibroblasts transfected with retroviral vectors and grown on collagen latphosphate receptors. 2 In keeping with this, it has been shown that the administration of purified lysosomal tices which were implanted in the peritoneal cavity successfully secreted ␤-glucuronidase and corrected the enzymes to the culture medium can correct the enzymatic defect in fibroblasts from patients with various types of storage lesions in the liver and spleen of mucopolysaccharidosis VII mice. 5 The same approach resulted in long-LSD. 3, 4 This ability of cells to take up the enzyme has provided the basis for the use of replacement therapy for term secretion of this enzyme in dogs 6 and similar results were obtained in nude mice transplanted with neothis group of disorders. In the case of Fabry disease, early studies showed that ␣-gal partially purified from various organs which were secreting ␣-l-iduronidase.
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Since the discovery that skeletal muscle can be transsources is taken up by skin fibroblasts from Fabry hemizygotes when added to the culture medium and does fected in vivo by intramuscular injection of plasmid DNA, [8] [9] [10] this organ system has attracted considerable catabolize the accumulated substrate, globotriaosylceramide (CTH). This prompted several clinical trials of attention as a potential source of secreted therapeutic proteins. Injection of plasmid DNA constructs has been used successfully for the expression of dystrophin, 11 factor VII, human growth hormone, 15 factor IX, 16 ␤-glucuronidase, human and murine erythropoietin 17, 18 and human gluco- (sense) or in the reverse orientation (antisense) as indicated. For the generation of pX3F, pX4F and pIVGF, the cDNA coding for ␣-gal was amplified by RT-PCR and cloned in pCRII
Effect of muscle-specific regulatory (Invitrogen, DeSchelp, The Netherlands), 27 resulting in pGal-wt.
elements
EcoRI digestion of pGal-wt releases the ␣-gal cDNA without flanking sequences which was used in the appropriate vectors.
We have made several vectors driving the expression of elements, due to the ability of these myoblasts to undergo fusion and differentiation under certain culture conditions. Once mature myotubes are formed, they cannot be transfected by nonviral methods. Therefore, the stancells, but exerts little or no enhancing effect in undifferendard transfection protocol starts with transfection of tiated myoblasts. We have also compared the expression undifferentiated myoblasts with cationic liposomes follevels generated by pX3F and pX4F, which only differ in lowed by differentiation to mature myotubes. 25 Gene the orientation of the MLC1/3 enhancer. Both constructs expression can be measured at any time-point during the showed the same activity after 6 days in differentiation differentiation process, so that this system also allows a medium (Figure 2) , confirming that the orientation of the comparison of the activity of regulatory elements before enhancer does not affect the levels of expression. This and after the activation of muscle-specific genes. Howsupports previous data showing that this enhancer ever, transfection efficiency must be carefully controlled increases the activity of the SV40 promoter 30 in mature by cotransfection with a different plasmid driving the myotubes in an orientation-independent manner and expression of a reporter gene. This is used as an internal suggests that muscle differentiation provides the necescontrol which corrects for the differences between consary muscle-specific factors which enable this element to structs and between plates.
enhance the basal activity of heterologous promoters. We first compared three constructs containing a muscle-specific promoter (rabbit myosin heavy chain) or the human cytomegalovirus promoter combined with the Secretion of human ␣-gal to the culture myosin light chain 1/3 enhancer (see Table 1 for details medium and uptake by ␣-gal-deficient of the constructs). The MLC1/3 enhancer has been shown fibroblasts to result in muscle-specific expression of heterologous genes in transgenic mice and zebrafish. 28, 29 In a different set of experiments, we have assayed the total activity of ␣-gal in cell extracts and in supernatants The construct in which ␣-gal expression is driven by the CMV promoter alone (pIVGF) showed the highest conditioned for 48 h after transfection with constructs pX3F, pX4F or pX7F, relative to controls (mock transactivity in undifferentiated myoblasts (18 h after transfection), followed by pX4F and pMCagalF in this fected, no DNA). The total amount of ␣-gal activity in the culture medium of transfected cells was significantly order (Figure 1a) . In contrast, the analysis of fully differentiated myotubes (10 days after transfection) revealed higher than in controls (average of the three constructs, 2.17 U versus 0.10 U in controls, results not shown). In that ␣-gal enzymatic activity was clearly higher in pX4F than in pIVGF (Figure 1b) , the only difference between order to confirm that the ␣-gal expressed and secreted in vitro has undergone correct post-translational processing, both constructs being the presence of the MLC1/3 enhancer in pX4F. Our results show that this enhancer we investigated the ability of ␣-gal-deficient fibroblasts to take up the enzyme from medium conditioned by C2C12 element can increase the strength of the expression driven by the CMV promoter in differentiated myogenic myoblasts transfected with pX7F. Fibroblasts from a hem- Table 1 
(Gibco). After 30 min incubation at room temperature, the mixture was diluted up to 1 ml in optimem-1 and added to the cells. Transfections were carried out for 6-8 h at 37°C/5% CO2 and included pCMV-␤ (typically 200 ng in 2 g of total DNA) which drives the expression of beta-gal. The latter was used as an internal control of transfection efficiency. After transfection, plates were washed with PBS followed by addition of DMEM/2% horse serum (differentiation medium). Under these conditions, myoblasts start the process of fusion and differentiation into myotubes, which become visible after 48 h and continue to develop for 4-6 days. Enzymatic activities of alpha-gal and beta-gal in cell extracts were assayed fluorimetrically with specific substrates, so that neither reaction showed any cross-reactivity. Normalized alpha-gal enzymatic activity (in Units alpha-gal/Unit beta-gal) is shown 18 h after transfection (undifferentiated myoblasts). High-low bars show the results from duplicate experiments. (b) Comparison of constructs pIVGF, pX4F and pMCagalF after transfection of C2C12 myoblasts as indicated above. Normalized alpha-gal enzymatic activity (in Units alpha-gal/Unit beta-gal) is shown 10 days after transfection (fully differentiated myotubes). Note that the values reflect not only the change in alpha-gal but also the decrease in beta-gal (the reporter enzyme used to correct for transfection efficiency), which is driven by the CMV promoter alone. Therefore, the actual normalized units for each construct cannot be compared directly with the values obtained from undifferentiated myoblasts (shown in a). However, since all constructs are co-transfected with exactly the same amount of the same internal control plasmid, a direct comparison can be made between constructs at a given time-point after transfection. High-low bars show the results from duplicate experiments.

Normalized alpha-gal enzyProteins were measured using the bicinchonic acid method (Sigma). Error matic activity (in Units alpha-gal/Unit beta-gal) is shown 6 days after bars = s.e.m. (n = 6). *Significant difference (P Ͻ 0.01) with any of the transfection (fully differentiated myotubes). High-low bars show the other groups (Mann-Whitney ranks-sum test for unpaired samples). , results from duplicate experiments.
Control fibroblasts; ᮀ, conditioned medium; , conditioned medium + M6P.
izygous Fabry patient (which show low enzymatic activity) were cultured for 4 days in differentiation medium that had been conditioned by C2C12 myoblasts mock-transfected myoblasts (P Ͻ 0.01). This effect was completely abolished by the addition of mannose-6-phostransfected with pX7F. Figure 3 shows the ␣-gal enzymatic activity in fibroblasts kept under these conditions; phate (5 mm) to the conditioned medium (Figure 3) , showing that this increase in ␣-gal activity was the result significantly higher levels were detected in those cultured with medium conditioned by pX7F-transfected myoblasts of uptake of the enzyme via mannose-6-phosphate receptors. This strongly suggests that the enzyme contained than in those cultured with medium conditioned by appropriate post-translational modifications, such as genes can also trigger an immune response following their delivery in gene therapy. 31-33 Therefore, measures phosphomannosyl residues. To our knowledge, this is the first report in which a correctly glycosylated form of to prevent or combat immunogenicity of the targeted protein should be developed. Administration of several human ␣-gal was expressed and secreted from differentiated muscle cells. different immunomodulating agents, including immunosuppressive drugs and anti-CD4 or anti-CD40L antibodies at the time of gene therapy gave encouraging
Production of human ␣-gal after results. 32 Such a transient ablation of CD4 + T cells may intramuscular injection of plasmid DNA prevent the effector phase of immune response to the gene product. Moreover, some Fabry disease patients In order to see whether we could reproduce these results have missense mutations, possibly with some nonfuncin vivo, we have analysed ␣-gal activity in muscle extracts tional protein present. In these cases induction of from mice injected intramuscularly with plasmid DNA.
immune responses to the gene therapy product may be This technique does not permit a correction to be made prevented. for the number of transfected fibres as can be done in Apart from the immune reaction against transfected vitro. This requires the use of samples of adequate size fibres, other authors have shown that the activity of the in order to detect any potential statistical difference. In CMV promoter-driven expression declines after injection our experiment (six muscles in each group), injection of of plasmid constructs with reporter genes. In contrast, construct pX7F into the tibialis anterior resulted in signifivectors containing the RSV promoter showed more suscantly increased levels of ␣-gal activity with respect to tained expression. The reasons for this difference the control muscles injected with saline (P Ͻ 0.01) 7 days between promoters is not well understood, but promoter after injection (Figure 4) . Expression of foreign proteins shut-off has been proposed as a mechanism. 34 Although in muscle has been shown to elicit an immune response data obtained with the C2C12 cell line in vitro cannot be against those fibres expressing the protein, 22 which directly extrapolated to the situation in muscle, our decrease in number and disappear completely 2 weeks results suggest that the MLC1/3 enhancer element can after the injection. For this reason, we have allowed increase and prolong the expression driven by the CMV expression to proceed only for 1 week, analysing enzypromoter in conditions that resemble mature muscle matic activity well before the start of the effector phase of fibres. If this effect is also present in muscle in vivo, this the immune response against human ␣-gal. Preliminary could have interesting implications for the development results from our laboratory indicate that vectors containof vectors designed for direct plasmid injection in muscle, ing the mouse ␣-gal cDNA can drive the expression of because it could help to maintain the activity of the CMV the enzyme for at least 4 weeks in injected muscles (not promoter for a longer period of time. shown). The isogenic protein products of therapeutic In summary, our in vivo results show significantly increased production of ␣-gal in muscle after injection of a plasmid expression vector. Together with our data showing that muscle cells can secrete human ␣-gal in its correctly processed form, the results presented here represent a significant step towards the improvement of this expression system and the generation of a strategy for the production of ␣-gal from muscle in vivo. 
